Living-donor liver transplantation in patients with concurrent active tuberculosis at transplantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee Y.T. | - |
dc.contributor.author | Hwang S. | - |
dc.contributor.author | Lee S.-G. | - |
dc.contributor.author | Kim K.-W. | - |
dc.contributor.author | Choi N.-K. | - |
dc.contributor.author | Park G.-C. | - |
dc.contributor.author | Yu Y.-D. | - |
dc.contributor.author | Yoo J.-W. | - |
dc.contributor.author | Kim W.S. | - |
dc.contributor.author | Shim T.S. | - |
dc.date.available | 2020-11-03T07:44:20Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 1027-3719 | - |
dc.identifier.issn | 1815-7920 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/15476 | - |
dc.description.abstract | SETTING: Although active tuberculosis (TB) is a contra-indication for liver transplantation (LT), LT may be the only possible treatment option in patients with irreversible liver failure and concurrent TB. OBJECTIVES: To assess the outcome of LT in patients with concurrent TB and liver failure. METHODS: We retrospectively evaluated the clinical outcomes of nine LT recipients with concurrent TB in Korea, an intermediate TB burden country. RESULTS: The primary causes of living-donor LT (LDLT) in nine patients were anti-tuberculosis drugi nduced fulminant hepatic failure (n = 4) and end-stage liver disease (n = 5). The sites of active TB were the lungs (n = 5), lymph nodes (n = 3) and pleura (n = 1). After LDLT, most patients were treated with less hepatotoxic drugs, including fl uoroquinolones, ethambutol and cycloserine; none was treated with pyrazinamide. One patient experienced acute rejection, probably attributable to an interaction between rifampicin and cyclosporine. All nine patients, including one taking rifabutin, successfully completed anti-tuberculosis treatment and have been followed up for a median of 926 days after LDLT, without relapse of TB. CONCLUSION: When properly managed, the prognosis of LDLT recipients with concurrently active TB at transplantation is very favourable. The current protocol, which considers active TB an absolute contraindication for LT, should be modifi ed or relaxed, particularly for patients with LDLT. © 2010 The Union. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | International Union against Tubercul. and Lung Dis. | - |
dc.title | Living-donor liver transplantation in patients with concurrent active tuberculosis at transplantation | - |
dc.type | Article | - |
dc.publisher.location | 프랑스 | - |
dc.identifier.scopusid | 2-s2.0-77954694545 | - |
dc.identifier.bibliographicCitation | International Journal of Tuberculosis and Lung Disease, v.14, no.8, pp 1039 - 1044 | - |
dc.citation.title | International Journal of Tuberculosis and Lung Disease | - |
dc.citation.volume | 14 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1039 | - |
dc.citation.endPage | 1044 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | cycloserine | - |
dc.subject.keywordPlus | ethambutol | - |
dc.subject.keywordPlus | isoniazid | - |
dc.subject.keywordPlus | quinoline derived antiinfective agent | - |
dc.subject.keywordPlus | rifabutin | - |
dc.subject.keywordPlus | rifamycin | - |
dc.subject.keywordPlus | tuberculostatic agent | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | clinical article | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | graft rejection | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | liver cell carcinoma | - |
dc.subject.keywordPlus | liver failure | - |
dc.subject.keywordPlus | liver transplantation | - |
dc.subject.keywordPlus | living donor | - |
dc.subject.keywordPlus | lung | - |
dc.subject.keywordPlus | lung tuberculosis | - |
dc.subject.keywordPlus | lymph node | - |
dc.subject.keywordPlus | lymph node biopsy | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | outcome assessment | - |
dc.subject.keywordPlus | pleura | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | treatment duration | - |
dc.subject.keywordPlus | tuberculous lymphadenitis | - |
dc.subject.keywordPlus | comparative study | - |
dc.subject.keywordPlus | complication | - |
dc.subject.keywordPlus | graft rejection | - |
dc.subject.keywordPlus | incidence | - |
dc.subject.keywordPlus | isolation and purification | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | Liver Failure, Acute | - |
dc.subject.keywordPlus | liver transplantation | - |
dc.subject.keywordPlus | living donor | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | Mycobacterium tuberculosis | - |
dc.subject.keywordPlus | procedures | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordPlus | tuberculosis | - |
dc.subject.keywordPlus | young adult | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Antitubercular Agents | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Follow-Up Studies | - |
dc.subject.keywordPlus | Graft Rejection | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Incidence | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | Liver Failure, Acute | - |
dc.subject.keywordPlus | Liver Transplantation | - |
dc.subject.keywordPlus | Living Donors | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Mycobacterium tuberculosis | - |
dc.subject.keywordPlus | Retrospective Studies | - |
dc.subject.keywordPlus | Treatment Outcome | - |
dc.subject.keywordPlus | Tuberculosis | - |
dc.subject.keywordPlus | Young Adult | - |
dc.subject.keywordAuthor | Liver transplantation | - |
dc.subject.keywordAuthor | Living donors | - |
dc.subject.keywordAuthor | Tuberculosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.